Loading clinical trials...

A Study for Patients With Secondary Progressive Multiple Sclerosis | Clinical Trials | Clareo Health

COMPLETEDPHASE2/PHASE3

A Study for Patients With Secondary Progressive Multiple Sclerosis

A Double-Blind, Placebo Controlled Multicentre Study To Evaluate The Efficacy And Safety Of MBP8298 In Subjects With Secondary Progressive Multiple Sclerosis

NCT00869726•Eli Lilly and Company

View on ClinicalTrials.gov

Summary

The purpose of this study is to determine whether MBP8298 is effective and safe in the treatment secondary progressive multiple sclerosis. Dirucotide is generic name for MBP8298.

Eligibility

Age

18 - 65 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Documented history of SPMS
•Absence of relapse in the 3mos prior to baseline
•EDSS of 3.5 - 6.5
•Pyramidal or Cerebellar FSS greater than or equal to 3
•A cohort of 100 HLA DR2/4 negative patients is required. Once enrollment to this cohort is complete, all further patients are required to be HLA DR2/4 positive.
•Informed consent
•Subject reliability and compliance

Exclusion Criteria

•Diagnosis of Primary Progressive MS
•Subjects have previously received MBP8298
•Recent history of malignancy, with the exclusion on basal cell carcinoma.
•Steroid therapy within 30 days prior to first study specific procedure or any other treatment known to be used for putative or experimental MS treatment
•Therapy with beta-interferon, glatiramer acetate within 3 mos or mitoxantrone, cyclophosphamide, methotrexate, azathioprine, or any other immuno-modulating or immunosuppressive drugs including recombinant or non-recombinant cytokines or plasma exchange within 6 mos prior to performance of the first study-specific test, with the exception of corticosteroids or ACTH for relapse treatment.
•Initiation or discontinuation of therapy with 4-AP or 3,4-DAP at any time during the study period.
•History of anaphylactic/anaphlactoid reactions to glatiramer acetate
•Abnormal lab values at the Screening Visit deemed by the Investigator to be clinically significant
•Known allergy to Gadolinium-DTPA
•Treatment at any time with Cladribine, total lymphoid irradiation, monoclonal antibody treatment
+9 more criteria

Locations (10)

St. Michaels Hospital

Toronto, Ontario, Canada

Copenhagen University Hospital

Copenhagen, Denmark

West Tallinn Central Hospital

Tallinn, Estonia

Terveystalo Turku Kuvantaminen

Turku, Finland

Heinrich Heine Universitaets

Düsseldorf, Germany

Vecmilgravis Hospital

Riga, Latvia

Maaslandziekenhuis

Sittard, Netherlands

Hospital Duran I Reynals

Barcelona, Spain

Karolinska Universitetssjukhus

Stockholm, Sweden

Walton Hospital

Liverpool, United Kingdom

Key Dates

Start Date

December 1, 2004

Primary Completion Date

May 1, 2009

Completion Date

May 1, 2009

Last Updated

June 2, 2010

Enrollment

596

ACTUAL participants

Conditions

Secondary Progressive Multiple Sclerosis

Interventions

dirucotide

DRUG

Placebo

DRUG

A Study to Evaluate the Efficacy and Safety of Remibrutinib in Secondary Progressive Multiple Sclerosis

NCT07225504

Secondary Progressive Multiple Sclerosis (SPMS)

View study

RECRUITINGPHASE3

Best Available Therapy Versus Autologous Hematopoietic Stem Cell Transplant for Multiple Sclerosis (BEAT-MS)

NCT04047628

Relapsing Multiple SclerosisRelapsing Remitting Multiple Sclerosis+1 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: June 2, 2010Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

A Study for Patients With Secondary Progressive Multiple Sclerosis

Inclusion Criteria

Exclusion Criteria

A Study to Evaluate the Efficacy and Safety of Remibrutinib in Secondary Progressive Multiple Sclerosis

Best Available Therapy Versus Autologous Hematopoietic Stem Cell Transplant for Multiple Sclerosis (BEAT-MS)

Special Drug-use Surveillance for Kesimpta for s.c. Injection 20 mg Pen

Metformin Treatment in Progressive Multiple Sclerosis

Multiple Sclerosis-Simvastatin Trial 2

Exploring the Efficacy and Safety of Siponimod in Patients With Secondary Progressive Multiple Sclerosis (EXPAND)